Liu Feiyu, Wang Chaoyang, Hu Tao, Wang Wei
Department of Pharmacy Department of Thoracic Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Medicine (Baltimore). 2018 Apr;97(15):e0397. doi: 10.1097/MD.0000000000010397.
Lung cancer is the leading cause of cancer-related deaths in the world, and non-small cell lung cancer accounts for > 75% of all lung cancer cases. Cisplatin-based concurrent chemoradiotherapy has become the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Third-generation chemotherapy agents plus cisplatin have been most commonly used in concurrent chemoradiotherapy, which is also associated with more adverse effects and acute toxicities. S-1 as an oral chemotherapeutic agent exhibits higher antitumor activity, less adverse effects, and better biological availability. Recently, studies illustrated S-1-based concurrent chemoradiotherapy also had excellent effects in the treatment of locally advanced NSCLC.
A systematic literature search will be performed through February 2018 using MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Google Scholar for relevant articles published in any language. Randomized controlled trials and prospective comparative studies will be included. All meta-analyses will be performed using Review Manager software. The quality of the studies will be evaluated using the guidelines listed in the Cochrane Handbook. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements will be followed until the findings of the systematic review and meta-analysis are reported.
The results of this systematic review and meta-analysis will be published in a peer-reviewed journal.
Our study will draw an objective conclusion of the efficacy and safety of S-1-based chemoradiotherapy in the treatment of locally advanced unresectable NSCLC and provides level I evidence for clinical decision makings.
肺癌是全球癌症相关死亡的主要原因，非小细胞肺癌占所有肺癌病例的75%以上。以顺铂为基础的同步放化疗已成为局部晚期非小细胞肺癌（NSCLC）的标准治疗方法。第三代化疗药物联合顺铂最常用于同步放化疗，这也伴随着更多的不良反应和急性毒性。S-1作为一种口服化疗药物，具有更高的抗肿瘤活性、更少的不良反应和更好的生物利用度。最近，研究表明基于S-1的同步放化疗在局部晚期NSCLC的治疗中也有出色的效果。
将通过2018年2月前使用MEDLINE、EMBASE、Cochrane对照试验中央注册库和谷歌学术搜索系统检索以任何语言发表的相关文章。将纳入随机对照试验和前瞻性比较研究。所有荟萃分析将使用Review Manager软件进行。将使用Cochrane手册中列出的指南评估研究质量。在报告系统评价和荟萃分析的结果之前，将遵循系统评价和荟萃分析的首选报告项目声明。
本系统评价和荟萃分析的结果将发表在同行评审期刊上。
我们的研究将对基于S-1的放化疗治疗局部晚期不可切除NSCLC的疗效和安全性得出客观结论，并为临床决策提供一级证据。
